These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26636329)

  • 1. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
    Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
    Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
    Liu Z; Markham M; Mandernach MW
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
    Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
    Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
    [No Abstract]   [Full Text] [Related]  

  • 4. Meningeal marginal zone B-cell lymphoma: The meningioma trap.
    Villeneuve A; Rubin F; Bonfils P
    Eur Ann Otorhinolaryngol Head Neck Dis; 2018 Apr; 135(2):131-132. PubMed ID: 29331570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
    Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
    QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucosa-associated lymphoid tissue lymphoma with unusual
    Zhang NS; Shi F; Kong L; Zhu H
    World J Gastroenterol; 2017 Jan; 23(3):551-559. PubMed ID: 28210093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
    Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Cencini E; Fabbri A; Schiattone L; Bocchia M
    Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
    [No Abstract]   [Full Text] [Related]  

  • 13. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Iannitto E; Ferrero S; Bommier C; Drandi D; Ferrante M; Bouabdallah K; Carras S; Gini G; Camus V; Mancuso S; Marcheselli L; Ferrari A; Merli M; Tessoulin B; Stelitano C; Beldjord K; Roti G; Jardin F; Castagnari B; Palombi F; Baseggio L; Traverse-Glehen A; Tripodo C; Liberati AM; Parolini M; Usai S; Patti C; Federico M; Musso M; Ladetto M; Zucca E; Thieblemont C
    Haematologica; 2024 Jul; 109(7):2297-2302. PubMed ID: 38497158
    [No Abstract]   [Full Text] [Related]  

  • 14. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Hsu A; Kurt H; Zayac AS; Olszewski AJ
    Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
    Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
    Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
    Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
    Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
    Cheah CY; Opat S; Trotman J; Marlton P
    Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal change disease associated with MALT lymphoma.
    Kasmani R; Marina VP; Abidi S; Johar B; Malhotra D
    Int Urol Nephrol; 2012 Dec; 44(6):1911-3. PubMed ID: 21594766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.